ClinicalTrials.gg
CompletedNCT02905331Updated Feb 4, 2025Results posted

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

A Phase 3 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
19th of 29
78 · median 120
Started
2017
with 1 other
Phase 3
12 of 29
none open now
Registered
9th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one is the 19th largest by enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A woman of must have a negative urine pregnancy test (beta-human chorionic gonadotropin) at screening and at Week 0
  • Before randomization, a woman must be either: a) Not of childbearing potential: premenarchal; (greater than [>] 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle-stimulating hormone level (FSH) >40 International Units Per Liter [IU/L]); permanently sterile (example, tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy, b) Of childbearing potential and practicing a highly effective method of , consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: example, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/ film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant)
  • Agree not to receive a Bacillus Calmette Guerin (BCG) vaccination during the study, or within 12 months after the last administration of study drug
  • Have a Psoriasis Area and Severity Index (PASI) greater than or equal to [>=] 12 at screening and at baseline
  • Have an involved body surface area (BSA) >= 10 percent (%) at screening and at baseline

Exclusion criteria

Exclusion Criteria:

  • Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
  • Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
  • Has a transplanted organ (with exception of a corneal transplant >3 months before the first administration of study drug)
  • Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
  • Has received any anti-tumor necrosis factor alpha (TNF-alpha) biologic therapy within 3 months before the first administration of study drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Group 1 (Guselkumab: Placebo)

    Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 2 (Placebo: Guselkumab)

    Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.

    Also known as: CNTO 1959

  • DrugPlacebo

    Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure. Participants who discontinued study drug due to lack of efficacy, an adverse event (AE) of worsening of psoriasis, or who started a protocol-prohibited medication/therapy during study that could improve psoriasis were considered as treatment failures for the study.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent (%) to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) were considered IGA cleared responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

    Time frame: Week 16

  2. Percentage of Participants Who Achieve a PASI 100 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with 100% improvement in PASI from baseline (PASI score=0) were considered PASI 100 responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

    Time frame: Week 16

  3. Percentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

    Time frame: Week 16

  4. Percentage of Participants Who Achieve a PASI 50 Response and a PASI 75 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with \>=50% and \>= 75% improvement in PASI from baseline were considered PASI 50 and PASI 75 responders respectively. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

    Time frame: Week 16

  5. Percent Improvement From Baseline in PASI Score at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received.

    Time frame: Baseline and Week 16

  6. Percent Improvement From Baseline in PASI Score Through Week 40

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

    Time frame: Baseline, Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended every 8 weeks [q8w] dosing interval)

  7. Percentage of Participants Who Achieved an IGA Score of Cleared (0), Cleared (0) or Minimal (1) and Mild or Better (<=2) Through Week 40

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders while those achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

    Time frame: Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)

  8. Percentage of Participants Who Achieved PASI 100 Responses, PASI 90 Responses, PASI 75 Responses, and PASI 50 Responses

    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and \>= 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

    Time frame: Week 4, 8, 12, 16, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)

07

Results

Posted Sep 6, 2018

Participant flow

Placebo Controlled Period(Week[wk] 0-16)
Participant flow — Placebo Controlled Period(Week[wk] 0-16)
MilestonePlaceboGuselkumabPlacebo to Guselkumab
Started16620
Completed13610
Not completed310
Withdrew: Adverse event100
Withdrew: Lack of efficacy200
Withdrew: Lost to follow-up010
Active Treatment and Follow up (wk16-40)
Participant flow — Active Treatment and Follow up (wk16-40)
MilestonePlaceboGuselkumabPlacebo to Guselkumab
Started06113
Completed05313
Not completed080
Withdrew: Other060
Withdrew: Withdrawal by subject020

Outcome measures

PrimaryPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure. Participants who discontinued study drug due to lack of efficacy, an adverse event (AE) of worsening of psoriasis, or who started a protocol-prohibited medication/therapy during study that could improve psoriasis were considered as treatment failures for the study.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
Percentage of participantsPlaceboGuselkumab
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16080.6
Statistical analysis
  • Placebo vs Guselkumab · Fisher Exact · p = <0.001
PrimaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent (%) to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Percentage of participantsPlaceboGuselkumab
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16075.8
Statistical analysis
  • Placebo vs Guselkumab · Fisher Exact · p = < 0.001
SecondaryPercentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) were considered IGA cleared responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16
Percentage of participantsPlaceboGuselkumab
Percentage of Participants Who Achieve an IGA Score of Cleared (0) at Week 16056.5
SecondaryPercentage of Participants Who Achieve a PASI 100 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with 100% improvement in PASI from baseline (PASI score=0) were considered PASI 100 responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve a PASI 100 Response at Week 16
Percentage of participantsPlaceboGuselkumab
Percentage of Participants Who Achieve a PASI 100 Response at Week 16050.0
SecondaryPercentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16
Percentage of participantsPlaceboGuselkumab
Percentage of Participants Who Achieved an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) at Week 16093.5
SecondaryPercentage of Participants Who Achieve a PASI 50 Response and a PASI 75 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with \>=50% and \>= 75% improvement in PASI from baseline were considered PASI 50 and PASI 75 responders respectively. Non-responder imputation (counted as non-responders) was applied for participants who met treatment failure rules, as well as for remaining missing data after treatment failure.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve a PASI 50 Response and a PASI 75 Response at Week 16
Percentage of participantsPlaceboGuselkumab
PASI 50 responders093.5
PASI 75 responders088.7
SecondaryPercent Improvement From Baseline in PASI Score at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received.

Time frame:
Baseline and Week 16
Reported as:
Mean · Percent improvement
Percent Improvement From Baseline in PASI Score at Week 16
Percent improvementPlaceboGuselkumab
Percent Improvement From Baseline in PASI Score at Week 168.72 ± 18.22991.53 ± 16.756
Statistical analysis
  • Placebo vs Guselkumab · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryPercent Improvement From Baseline in PASI Score Through Week 40

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

Time frame:
Baseline, Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended every 8 weeks [q8w] dosing interval)
Reported as:
Mean · Percent improvement
Percent Improvement From Baseline in PASI Score Through Week 40
Percent improvementPlaceboGuselkumab
Week 45.58 ± 13.97040.99 ± 26.377
Week 810.45 ± 21.54071.76 ± 26.984
Week 1213.76 ± 24.14384.97 ± 20.520
Week 2062.65 ± 20.76094.77 ± 13.179
Week 2488.74 ± 12.09295.89 ± 10.164
Week 2895.68 ± 6.16296.30 ± 7.504
Week 3296.16 ± 5.60296.64 ± 7.143
Week 4097.70 ± 3.44392.47 ± 13.289
SecondaryPercentage of Participants Who Achieved an IGA Score of Cleared (0), Cleared (0) or Minimal (1) and Mild or Better (<=2) Through Week 40

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved an IGA score of cleared (0) or minimal (1) were considered IGA cleared or minimal responders while those achieved an IGA score of cleared (0), minimal (1), or mild (2) were considered IGA mild or better responders. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

Time frame:
Week 4, 8, 12, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an IGA Score of Cleared (0), Cleared (0) or Minimal (1) and Mild or Better (<=2) Through Week 40
Percentage of participantsPlaceboGuselkumab
Week 4: IGA of cleared (0)04.8
Week 4: IGA of cleared (0) or minimal (1)019.4
Week 4: IGA of mild or better (<=2)054.8
Week 8: IGA of cleared (0)019.4
Week 8: IGA of cleared (0) or minimal (1)056.5
Week 8: IGA of mild or better (<=2)12.585.5
Week 12: IGA of cleared (0)035.5
Week 12: IGA of cleared (0) or minimal (1)067.7
Week 12: IGA of mild or better (<=2)091.9
Week 20: IGA of cleared (0)067.7
Week 20: IGA of cleared (0) or minimal (1)46.285.5
Week 20: IGA of mild or better (<=2)92.393.5
Week 24: IGA of cleared (0)38.571.0
Week 24: IGA of cleared (0) or minimal (1)100.087.1
Week 24: IGA of mild or better (<=2)100.088.7
Week 28: IGA of cleared (0)61.564.5
Week 28: IGA of cleared (0) or minimal (1)100.087.1
Week 28: IGA of mild or better (<=2)100.095.2
Week 32: IGA of cleared (0)69.266.1
Week 32: IGA of cleared (0) or minimal (1)92.382.3
Week 32: IGA of mild or better (<=2)100.090.3
Week 40: IGA of cleared (0)61.553.2
Week 40: IGA of cleared (0) or minimal (1)92.371.0
Week 40:IGA of mild or better (<=2)100.079.0
SecondaryPercentage of Participants Who Achieved PASI 100 Responses, PASI 90 Responses, PASI 75 Responses, and PASI 50 Responses

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and \>= 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively. Participants were analyzed according to the assigned treatment to which they were randomized, regardless of the treatment they actually received. From week 20, participants in placebo group, only included participants who crossed over to receive guselkumab at week 16.

Time frame:
Week 4, 8, 12, 16, 20, 24, 28, 32, and Week 40 (4 weeks beyond the recommended q8w dosing interval)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI 100 Responses, PASI 90 Responses, PASI 75 Responses, and PASI 50 Responses
Percentage of participantsPlaceboGuselkumab
Week 4: 100% improvement03.2
Week 4: >= 90% improvement04.8
Week 4: >= 75% improvement012.9
Week 4: >= 50% improvement033.9
Week 8: 100% improvement016.1
Week 8: >= 90% improvement033.9
Week 8: >= 75% improvement056.5
Week 8: >= 50% improvement6.380.6
Week 12: 100% improvement030.6
Week 12: >= 90% improvement054.8
Week 12: >= 75% improvement077.4
Week 12: >= 50% improvement12.590.3
Week 16: 100% improvement050.0
Week 16: >=90% improvement075.8
Week 16: >=75% improvement088.7
Week 16: >=50% improvement093.5
Week 20: 100% improvement066.1
Week 20: >=90% improvement7.785.5
Week 20: >=75% improvement30.891.9
Week 20: >=50% improvement69.295.2
Week 24: 100% improvement30.871.0
Week 24: >=90% improvement61.582.3
Week 24: >=75% improvement84.688.7
Week 24: >=50% improvement100.095.2
Week 28: 100% improvement53.864.5
Week 28: >=90% improvement84.685.5
Week 28: >=75% improvement100.095.2
Week 28: >50% improvement100.096.8
Week 32: 100% improvement61.564.5
Week 32: >=90% improvement84.685.5
Week 32: >=75% improvement100.090.3
Week 32: >=50% improvement100.093.5
Week 40: 100% improvement53.853.2
Week 40: >=90% improvement100.066.1
Week 40: >=75% improvement100.079.0
Week 40: >=50% improvement100.079.0

Adverse events

Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Week 0-16)0/16 (0%)0/16 (0%)12/16 (75%)
Guselkumab (Week 0-16)0/62 (0%)2/62 (3.2%)38/62 (61.3%)
Placebo to Guselkumab (Week 16-40)0/13 (0%)2/13 (15.4%)8/13 (61.5%)
Guselkumab (Week 16-40)0/61 (0%)1/61 (1.6%)24/61 (39.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Week 0-16)Guselkumab (Week 0-16)Placebo to Guselkumab (Week 16-40)Guselkumab (Week 16-40)
Angina PectorisCardiac disorders0/160/621/130/61
DiverticulitisInfections and infestations0/160/621/130/61
Drug HypersensitivityImmune system disorders0/160/620/131/61
Chest DiscomfortGeneral disorders0/161/620/130/61
Chest PainGeneral disorders0/161/620/130/61
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlacebo (Week 0-16)Guselkumab (Week 0-16)Placebo to Guselkumab (Week 16-40)Guselkumab (Week 16-40)
Injection Site PainGeneral disorders7/1625/623/1311/61
Injection Site ColdnessGeneral disorders3/1614/622/137/61
Injection Site PruritusGeneral disorders2/168/621/132/61
Injection Site IndurationGeneral disorders2/167/621/132/61
Injection Site ErythemaGeneral disorders1/167/620/134/61
Injection Site SwellingGeneral disorders1/167/621/133/61
Viral Upper Respiratory Tract InfectionInfections and infestations0/163/621/136/61
Upper Respiratory Tract InfectionInfections and infestations0/165/620/131/61
AnaemiaBlood and lymphatic system disorders0/160/621/131/61
Left Ventricular HypertrophyCardiac disorders0/160/621/130/61

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboGuselkumabTotal
Mean45.4 ± 15.746.2 ± 12.9246 ± 13.43
Age, Customized
Age, Customized(Participants)PlaceboGuselkumabTotal
>=18 to 65 years145872
>=65 years246
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGuselkumabTotal
Female42125
Male124153
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGuselkumabTotal
Hispanic or Latino123
Not Hispanic or Latino156075
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGuselkumabTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American112
White135770
More than one race011
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGuselkumabTotal
Asian235
Black or African American112
Hispanic or Latino022
Other011
White Non-Hispanic135568
Region of Enrollment
Region of Enrollment(Participants)PlaceboGuselkumabTotal
Canada51924
Poland52025
United States62329
08

Study locations

14 sites
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Indiana Clinical Trial Center
    Plainfield, Indiana 46168, United States
  • Dermatology Specialists
    Louisville, Kentucky 40241, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • University of Pittsburgh Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Partners
    Johnston, Rhode Island 02919, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Dr. Chih ho Hong Medical
    Surrey, British Columbia V3R 6A7, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • DermEdge Research
    Mississauga, Ontario L4Y 4C5, Canada
  • Niepubliczny Zaklad Opieki Zdrowotnej Osteo-Medic s.c. Artur Racewicz i Jerzy Supronik
    Bialystok, 15 351, Poland
  • Szpital Uniwersytecki nr 1 im Dr A Jurasza
    Bydgoszcz, 85 094, Poland
  • Wromedica Irena Bielicka, Janusz Szczepanik S.C.
    Wroclaw, 51-685, Poland
09

References and documents

Publications

  • Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020 Mar;31(2):152-159. doi: 10.1080/09546634.2019.1587145. Epub 2019 Mar 19. PubMed 30887876 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Feb 2018, 11 months.

Results were first posted in Sep 2018, 7 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 19, 2016
StartActual
Feb 28, 2017
Primary completionActual
Feb 6, 2018
CompletionActual
Feb 6, 2018
Results first posted
Sep 6, 2018
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02905331
Responsible party
Sponsor
First posted
Sep 19, 2016
Start date
Feb 28, 2017
Primary completion
Feb 6, 2018
Completion
Feb 6, 2018
Results posted
Sep 6, 2018
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion